Skip to main content

Table 1 HiBalance program design differences between the efficacy and effectiveness-implementation stages

From: Evaluation and implementation of highly challenging balance training in clinical practice for people with Parkinson’s disease: protocol for the HiBalance effectiveness-implementation trial

Program feature HiBalance-RCT (Efficacy phase) HiBalance-clinical setting (Effectiveness/Implementation phase)
Inclusion criteria Idiopathic Parkinson’s disease Idiopathic Parkinson’s disease
Hoehn & Yahr score of 2 or 3 Hoehn & Yahr score of 2 or 3
Able to walk independently indoors without an aid Able to walk independently indoors without an aid
Mini-Mental State examination score > 24 points Cognitively capable of following instructions in a group setting
Age ≥60 years All Ages
Core components Individually adapted, highly challenging and progressive balance training in 3 blocks with progressively integrated dual-task training Individually adapted, highly challenging and progressive balance training in 3 blocks with progressively integrated dual-task training
Dose 30 h of group training
(3 x 1 h sessions/week x 10 weeks)
20 h of group training (2 x 1 h sessions/week x 10 weeks) 10 h home exercise program (1 h/week x 10 weeks)
Providers Physical therapist PhD students (site responsible) and clinicians Physical therapist clinicians
Sites 2 sites, one university hospital 4–6 clinical sites/primary care clinics
Outcome evaluation
Performance-based
Balance performance Mini-BESTest score Mini-BESTest score
Modified figure of eight test
Physical activity level Steps per day measured by accelerometer Steps per day measured by accelerometer
Self-reported
Fear of falling/balance confidence Falls Efficacy Scale-International
(FES-I)
(A measure of concerns about falling)
Activities-specific balance confidence scale (ABC scale)
(A measure of balance confidence)
Activities of daily living Unified Parkinson’s Disease Rating Scale (UPDRS)- ADL component  
Self-rated health
Walking
Evaluation method
SF-36/PDQ-39
PDQ-39
Randomized controlled trial
EQ-5D-3 L
Walking impact scale (Walk 12G)
Non-randomized controlled design